Key result
DOAC switchers report high satisfaction but ~25% express adverse event concerns, particularly those under 60.
Why the study?
Patients on vitamin K antagonists face decisions about switching to direct oral anticoagulants, but treatment satisfaction and patient concerns after switching were not well characterized.
What are the treatment satisfaction and concerns among patients who switch from vitamin K antagonists to direct oral anticoagulants?
Comparison
Switched from VKA to DOAC
Design
Cross-sectional questionnaire study
Authors
Loading...
Concerns after VKA-to-DOAC switch, especially in patients <60 years, may warrant counseling; cross-sectional data leave open effects on adherence.
Cross-Sectional (n=1,399)
Yes
What are the treatment satisfaction and concerns among patients who switch from vitamin K antagonists to direct oral anticoagulants?
Patients switching from VKA to DOAC report high treatment satisfaction, though younger, female, and highly educated patients are more likely to express concerns about adverse events.
Toorop et al. (2020) conducted a cross-sectional in Thromboembolic diseases (n=1,399). Direct oral anticoagulants (DOACs) was evaluated on DOAC treatment satisfaction and concerns about adverse events. Among patients who switched from VKA to DOAC, treatment satisfaction was high (mean 8.8/10), but 25% expressed concerns about adverse events, particularly those aged <60 years (OR 4.1; 95% CI 2.6-6.4).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: